Back
CME
Optimizing Frontline Therapy in Ovarian Cancer Using PARP Inhibitors: A Video Roundtable
Watch this video roundtable with 3 experts discussing the latest clinical data informing the optimal management of patients with ovarian cancer using PARP inhibitors as frontline maintenance.
This educational program is intended for healthcare professionals practicing medicine outside of the United States.
Physicians: Maximum of 0.75 AMA PRA Category 1 Credit™
Released: May 21, 2021
Expiration: May 20, 2022
No longer available for credit.
Begin Activity
Share
Nicoletta Colombo, MD, PhD
Associate Professor of Obsterics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy
Thomas J. Herzog, MD
Associate Professor
Division of Gynecology
Washington University
St Louis, Missouri
Ignace Vergote, MD, PhD
Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium
Provided by
Provided by Clinical Care Options, LLC
Supporters
This educational activity is supported by an educational grant from
GlaxoSmithKline
This educational program is intended for ex-US gynecologic oncologists, medical oncologists, nurses, and other healthcare professionals who treat patients with ovarian cancer.
Upon completion of this activity, participants should be able to:
- Appraise the available data supporting the use of PARP inhibitors as frontline maintenance therapy for patients with and without BRCA-associated cancers
- Plan frontline maintenance therapy for patients with or without BRCA mutations or other defects in hom*ologous recombination repair
- Evaluate the differences among PARP inhibitors regarding evolving global indications, dosing, administration, efficacy, and treatment-related adverse events
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Nicoletta Colombo, MD, PhD
Associate Professor of Obsterics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy
Nicoletta Colombo, MD, has disclosed that she has received consulting fees from AstraZeneca, Biocad, Clovis, Eisai, GSK, Immunogen, Mersana, MSD/Merck, Pfizer, PharmaMar, Roche, Takeda, and Tesaro; Fees for Non-CME/CE Services from AstraZeneca, Novartis and Tesaro; and fees for research support from AstraZeneca, PharmaMar, and Roche.
Thomas J. Herzog, MD
Associate Professor
Division of Gynecology
Washington University
St Louis, Missouri
Thomas J. Herzog, MD, has disclosed that he has received consulting fees from Aravive, AstraZeneca, Caris, Clovis, Eisai, Genentech, GlaxoSmithKline, Merck, and Seagen.
Ignace Vergote, MD, PhD
Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven Belgium
Ignace Vergote, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Elevar, Genmab, GlaxoSmithKline, Immunogen, MSD, Oncoinvent, and Roche; and funds for research support from Genmab and Roche.
Staff
Megan Cartwright, PhD
Senior Clinical Editor
Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.
Katie Eustace, MBA
Senior Director,Global Medical Education, Europe
Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD
Editorial Director, Hematology/Oncology
Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD
Senior Managing Editor
Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Credit Designation
CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Participation in this self-study activity should be completed in approximately 0.75 hours.To successfully complete this activity and receive credit, participants must follow these steps during the period fromMay 21, 2021, through May 20, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate.After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page.Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Program Medium
This program has been made available online.
Goal
The goal of this program is to improve the knowledge and competence of global learners to optimally integrate current data needed to make treatment decisions and improve clinical outcomes in patients with ovarian cancer.
1 Item added to cart.
